Heather Anderson

ORCID: 0000-0001-8070-5323
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Cancer Treatment and Pharmacology
  • Cancer therapeutics and mechanisms
  • Neuroendocrine Tumor Research Advances
  • Lymphoma Diagnosis and Treatment
  • Liver Diseases and Immunity
  • Medication Adherence and Compliance
  • Pharmaceutical Practices and Patient Outcomes
  • Pediatric Hepatobiliary Diseases and Treatments
  • Pharmacogenetics and Drug Metabolism
  • Colorectal Cancer Treatments and Studies
  • Gastric Cancer Management and Outcomes
  • Health Systems, Economic Evaluations, Quality of Life
  • Gallbladder and Bile Duct Disorders
  • Neutropenia and Cancer Infections
  • Liver Disease Diagnosis and Treatment
  • Renal Transplantation Outcomes and Treatments
  • Pharmaceutical studies and practices
  • Multiple Myeloma Research and Treatments
  • Cancer Diagnosis and Treatment
  • Opioid Use Disorder Treatment
  • Drug-Induced Adverse Reactions
  • Viral-associated cancers and disorders

University of Montana
2013-2024

University of Colorado Anschutz Medical Campus
2013-2024

The Ohio State University
2024

Weill Cornell Medicine
2019

University of Colorado Denver
2011-2019

Cornell University
2019

Colorado School of Public Health
2011-2018

Virginia Department of Health
2017

Office of Minority Health and Health Equity
2017

University of Manitoba
2015

PURPOSE: We report the results of a prospectively randomized study that compared combination epirubicin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) (ECF) with mitomycin, PVI 5-FU (MCF) in previously untreated patients advanced esophagogastric cancer. PATIENTS AND METHODS: Five hundred eighty adenocarcinoma, squamous carcinoma, or undifferentiated carcinoma were to receive either ECF (epirubicin 50 mg/m 2 every 3 weeks, cisplatin 60 weeks 200 /d) MCF (mitomycin 7 6 300...

10.1200/jco.2002.08.105 article EN Journal of Clinical Oncology 2002-04-15

PURPOSE To evaluate the efficacy and safety of gemcitabine, a pyrimidine antimetabolite with activity against solid tumours. PATIENTS AND METHODS Eighty-two patients unresectable stage IIIa to IV non-small-cell lung cancer (NSCLC) were entered. The first 54 received gemcitabine 800 mg/m2, subsequent 1,000 as 30-minute intravenous infusion on days 0, 7, 14. Courses therapy repeated every 28 days. Twenty percent dosage escalation was permitted after course no.1 if World Health Organization...

10.1200/jco.1994.12.9.1821 article EN Journal of Clinical Oncology 1994-09-01

Vaccination against influenza and Streptococcus pneumoniae is recommended for elderly immunocompromised individuals. However, there little information concerning the efficacy of vaccination in specific groups patients. In this study, 52 patients underwent influenza, S. Haemophilus influenzae type b (Hib) as they attended hospital outpatient clinics. Serum was analysed prior to 4–6 weeks afterwards. Antibody titres Hib were compared with reference values corresponding geometric mean a healthy...

10.1054/bjoc.1999.1088 article EN cc-by-nc-sa British Journal of Cancer 2000-04-01

To determine the efficacy and tolerability of SPI-77 (sterically stabilised liposomal cisplatin) at three dose levels in patients with advanced non-small-cell lung cancer (NSCLC). Patients had Stage IIIB or IV NSCLC were chemo-naïve, Eastern Oncology Cooperative Group 0–2. The first cohort received 100 mg m−2, second 200 m−2 final 260 m−2. also pharmacokinetics analysis leucocyte platinum (Pt)-DNA adducts performed. Twenty-six treated, 22 being evaluable for response. Only one response...

10.1038/sj.bjc.6603345 article EN cc-by-nc-sa British Journal of Cancer 2006-09-12

Adherence to statins in real-world practice settings is known be suboptimal. However, less about how adherence changes over time and whether are associated with adverse cardiovascular (CV) outcomes.To (a) characterize yearly among initially adherent patients taking for primary prevention (b) assess the association between statin subsequent risk of CV events.A 10% random sample IMS LifeLink Health Plan Claims Database covering period from July 1, 1997, December 31, 2008, was used identify a...

10.18553/jmcp.2014.20.1.51 article EN Journal of Managed Care Pharmacy 2014-01-01

Abstract BACKGROUND The authors compared gemcitabine and carboplatin (GC) with mitomycin, ifosfamide, cisplatin (MIC) or vinblastine, (MVP) in patients advanced nonsmall cell lung carcinoma (NSCLC). primary objective was survival. Secondary objectives were time to disease progression, response rates, evaluation of toxicity, disease‐related symptoms, World Health Organization performance status (PS), quality life (QoL). METHODS Three hundred seventy‐two chemotherapy‐naïve International...

10.1002/cncr.11535 article EN Cancer 2003-06-16

To assess the efficacy of ciprofloxacin in neutropenic patients, we conducted a randomized prospective trial comparing combination and netilmicin against piperacillin plus as an empiric treatment fever cancer patients with neutropenia. Of 214 evaluable episodes, 115 99 were randomly assigned to arms, respectively. The overall response rates very similar (59 62% for respectively). gram-positive bacteremias was almost identical (around 40%); this low due part outbreak infection by multiply...

10.1128/aac.33.1.87 article EN Antimicrobial Agents and Chemotherapy 1989-01-01

Background: Rural Tennessee, especially rural East Tennessee has seen a dramatic increase in rates of controlled drug prescriptions and overdose deaths recent years. However, little is known about the individual decisions to prescribe or continue with relation addiction concerns. Objectives: The purpose this study was learn more what factors lead physicians' prescribing control drugs for non-cancer pain through use focus groups. Methods: A qualitative study, using groups, five family...

10.1080/10826084.2017.1342659 article EN Substance Use & Misuse 2017-08-31

Little is known about how many insured patients receive pharmacogenetic testing. We describe trends of single-gene testing in a US managed care population, and demographic clinical characteristics who received test.We leveraged random sample nearly 11 million from data set paid medical pharmacy claims to identify with at least one claim indicating receipt these tests: CYP2C19, CYP2D6, CYP2C9, VKORC1, UGT1A1, HLA class 1 typing.From January 2013 30 September 2017, 5712 test (55% female; mean...

10.1038/s41436-020-0788-3 article EN cc-by-nc-nd Genetics in Medicine 2020-04-14

ObjectiveTo describe the purpose, implementation, and perceived utility of course evaluations in pharmacy programs.MethodsAfter a literature review, 34-item survey was developed, pre-tested, sent to assessment administrators at accredited programs (N=139) with least three follow-ups. Descriptive inferential statistics were performed SPSS.ResultsNinety responded (64.7% response rate). Most students (94%) offered opportunity complete evaluations. Some completed during (47%) while others did so...

10.1016/j.ajpe.2024.100646 article EN American Journal of Pharmaceutical Education 2024-01-09

To learn how students in an accredited PharmD program the United States are using ChatGPT for personal, academic, and clinical reasons, whether think training should be incorporated into their program's curriculum.

10.1016/j.cptl.2024.102156 article EN cc-by-nc-nd Currents in Pharmacy Teaching and Learning 2024-07-18
Coming Soon ...